drugset / Trial / NCT05278156
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia
Phase 2
Completed
189 enrolled
Celon Pharma SA
National Center for Research and Development, Poland · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..
Timeline
- Start
- 2021-05-19
- Primary completion
- 2024-06-05
- Completion
- 2024-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPL500036 | Unknown | 20 mg | Oral |
| Subject | CPL500036 | Unknown | 40 mg | Oral |